One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel®

Clinical Endocrinology

Volumn 60, Issue 6, 2004, Pages 734-740

  Caron, P ^a   Bex, M ^b   Cullen, D R ^c   Feldt Rasmussen, U ^d   Pico Alfonso, A M ^e   Pynka, S ^f   Racz, K ^g   Schopohl, J ^h   Tabarin, A ⁱ   Valimaki, M J ^j  

^a CHU RANGUEIL   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d Rigshospitalet   (Denmark)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f POMERANIAN MEDICAL UNIVERSITY   (Poland)

^g SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ Hop du Haut Leveque ^*  (France)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 1;

ABDOMINAL PAIN; ACROMEGALY; ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE CONTROL; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MONITORING; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GALLBLADDER MUCOSA; GASTROINTESTINAL TOXICITY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT MONITORING; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PRURITUS; RADIOIMMUNOASSAY; REAL TIME ECHOGRAPHY; SEPSIS; SKIN INDURATION; STONE FORMATION; SUSTAINED DRUG RELEASE; TITRIMETRY;

ACROMEGALY; ADULT; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GALLBLADDER; GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 2942701886     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2004.02045.x     Document Type: Article

References (22)

1. Baldelli, R., Colao, A., Razzore, P., Jaffrain-Rea, M.-L., Marzullo, P., Ciccarelli, E., Ferretti, E., Ferone, D., Gaia, D., Camanni, F., Lombardi, G. & Tamburrano, G. (2000) Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). Journal of Clinical Endocrinology and Metabolism, 85, 4099-4103.
2. Barnard, L.B., Grantham, W.G., Lamberton, P., O'Dorisio, T.M. & Jackson, I.M. (1986) Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). Annals of Internal Medicine, 105, 856-861.
3. Cannavo, S., Squadrito, S., Curto, L., Almoto, B., Vieni, A. & Trimarchi, F. (2000) Results of a 2-year treatment with slow-release lanreotide in acromegaly. Hormone and Metabolic Research, 32, 224-229.
4. Caron, P., Cogne, M., Gusthiot-Joudet, B., Wakim, S., Catus, F. & Bayard, F. (1995) Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). European Journal of Endocrinology, 132, 320-325.
5. Caron, P., Morange-Ramos, I., Cogne, M. & Jaquet, P. (1997) Three-year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. Journal of Clinical Endocrinology and Metabolism, 82, 18-22.
6. Caron, P., Beckers, A., Cullen, D.R., Goth, M.I., Gutt, B., Lauberg, P., Pico, A.M., Valimaki, M. & Zgliczynski, W. (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 99-104.
7. Chanson, P., Leselbaum, A., Blumberg, J. & Schaison, G. (2000b) Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly: a 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. Pituitary, 2, 269-276.
8. Colao, A., Marzullo, P., Ferone, D., Marino, V., Pivonello, R., Di Somma, C., Di Sarno, A., Giaccio, A. & Lombardi, G. (1999) Effectiveness and tolerability of slow-release lanreotide treatment in active acromegaly. Journal of Endocrinological Investigation, 22, 40-47.
9. Colao, A., Ferone, D., Marzullo, P., Cappabianca, P., Cirillo, S., Boerlin, V., Lancranjan, I. & Lombardi, G. (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. Journal of Clinical Endocrinology and Metabolism, 86, 2779-2786.
10. Giusti, M., Gussoni, G., Cuttica, C.M. & Giordano, G. (1996) Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: 6-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. Journal of Clinical Endocrinology and Metabolism, 81, 2089-2097.
11. Harris, A.G., Prestele, H., Herold, K. & Boerlin, V. (1987) Long-term efficacy of Sandostatin (SMS 201-995, octreotide) in 178 acromegalic patients. Results from the International Multicentre Acromegaly Study Group. In: Sandostatin in the Treatment of Acromegaly: Consensus Round Table (ed. S. W. J. Lamberts), pp. 117-125. Springer-Verlag, Amsterdam.
12. Heron, I., Thomas, F., Dero, M., Gancel, A., Ruiz, J.M., Schatz, B. & Kuhn, J.M. (1993) Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 76, 721-727.
13. Ikuyama, S., Nawata, H., Kato, K., Ibayashi, H. & Nakagaki, H. (1986) Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. Journal of Clinical Endocrinology and Metabolism, 62, 729-733.
14. Lamberts, S.W., Uitterlinden, P. & Del Pozo, E. (1987) SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over 2 years. Journal of Clinical Endocrinology and Metabolism, 65, 703-710.
15. Lamberts, S.W., van der Lely, A.J., de Herder, W.W. & Hofland, L.J. (1996) Octreotide. New England Journal of Medicine, 334, 246-254.
16. Morange, I., De Boisvilliers, F., Chanson, P., Lucas, B., DeWailly, D., Catus, F., Thomas, F. & Jaquet, P. (1994) Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. Journal of Clinical Endocrinology and Metabolism, 79, 145-151.
17. Reubi, J.C. & Landolt, A.M. (1989) The growth hormone responses to octreotide in acromegaly correlate with adenoma sandostatin receptor status. Journal of Clinical Endocrinology and Metabolism, 68, 844-850.
18. Sassolas, G., Harris, A.G. & James-Deidier, A. (1990) Long-term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism, 71, 391-397.
19. Saveanu, A., Gunz, G., Dufour, H., Caron, P., Fina, F., Ouafik, L., Culler, M.D., Moreau, J.P., Enjalbert, A. & Jaquet, P. (2001) BIM-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. Journal of Clinical Endocrinology and Metabolism, 86, 140-145.
20. Spada, A., Arosio, M., Bochicchio, D., Bazzoni, N., Vallar, L., Bassetti, M. & Faglia, G. (1990) Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. Journal of Clinical Endocrinology and Metabolism, 71, 1421-1426.
21. Vance, M.L. & Harris, A.G. (1991) Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Archives of Internal Medicine, 151, 1573-1578.
22. Verhelst, J.A., Pedroncelli, A.M., Abs, R., Montini, M., Vandeweghe, M., Albani, G., Maiter, D., Pagani, M.D., Legros, J.J., Gianola, D., Bex, M., Poppe, K., Mockel, J. & Pagani, G. (2000) Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. European Journal of Endocrinology, 143, 577-584.